KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals' stock has been impacted by several events over the past six months. Chiesi Group announced an acquisition offer for $27.00 per share, leading to analyst downgrades and a 52-week high for KalVista's stock. The company presented at the Needham Virtual Healthcare Conference and reported inducement grants. Insider selling occurred to cover RSU tax obligations. Positive interim Phase 3 data was announced for the KONFIDENT-KID trial. KalVista reported strong EKTERLY launch and Q4/Full Year 2025 revenue, as well as Q3 2025 earnings per share exceeding expectations.

KalVista Pharmaceuticals has observed some seasonality in the demand for its products. The end of the year can involve "pull-forward activity" related to specialty pharmacy and patient behavior around re-authorizations and deductible resets. Weather-related disruptions in the first quarter have affected new patient starts, slowing prior authorizations and conversions due to physician office closures.

KalVista Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing oral therapies for rare diseases with unmet needs, particularly hereditary angioedema (HAE). Their primary product, EKTERLY (sebetralstat), is an orally delivered plasma kallikrein inhibitor approved in multiple major markets for on-demand treatment of acute HAE attacks in individuals aged 12 years and older. KalVista is also developing an orally disintegrating tablet formulation of sebetralstat and investigating its use in children aged 2 to 11. Additionally, the company has preclinical programs for oral Factor XIIa inhibitors and is exploring new treatments for other conditions such as thrombosis and inflammation.

KalVista Pharmaceuticals has its global corporate headquarters in Framingham, Massachusetts, United States, and maintains operations in Porton Down, United Kingdom; Salt Lake City, Utah, United States; Zug, Switzerland; and Tokyo, Japan. The company has initiated commercial launches of EKTERLY in the U.S., Germany, and Japan, and has granted Multicare Pharmaceuticals, LLC exclusive rights to commercialize sebetralstat in Latin America.

KalVista Pharmaceuticals has maintained a positive brand reputation over the past year due to the successful launch and adoption of EKTERLY, the first and only oral on-demand treatment for HAE. The strong early commercial launch of EKTERLY in the U.S. and Germany and positive interim Phase 3 data for pediatric patients have further bolstered its reputation. The acquisition offer from Chiesi Group also reflects a positive external valuation of KalVista's assets and prospects.

KalVista Pharmaceuticals' ownership is predominantly held by institutional investors, with 167 institutional owners and shareholders holding a total of 67,352,064 shares as of April 9, 2026. Major institutional owners include VR Adviser, LLC, Frazier Life Sciences Management, L.P., and Suvretta Capital Management, LLC. Insider ownership stood at around 2.90% as of May 2025, with insiders owning 4.3% as of May 2026.